ROCE Insights For PetMed Express
PetMed Express (NASDAQ:PETS) posted Q3 earnings of $9.29 million, an increase from Q2 of 11.25%. Sales dropped to $65.90 million, a 12.65% decrease between quarters. In Q2, PetMed Express earned $10.47 million, and total sales reached $75.44 million.
What Is ROCE?
Changes in earnings and sales indicate shifts in PetMed Express's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q3, PetMed Express posted an ROCE of 0.07%.
It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.
Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.
In PetMed Express's case, the positive ROCE ratio will be something investors pay attention to before making long-term financial decisions.
Q3 Earnings Insight
PetMed Express reported Q3 earnings per share at $0.38/share, which did not meet analyst predictions of $0.38/share.
See more from Benzinga
12 Consumer Discretionary Stocks Moving In Thursday's Pre-Market Session
12 Consumer Discretionary Stocks Moving In Wednesday's After-Market Session
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
